Roxee Meds Catalog
Velagliflozin Proline Monohydrate
Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.
Veterinary professional?
Source variance fields
- Active ingredients (Medication ingredients)
Data freshness
These are the storefront facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Source timing details
-
Storefront facts:
Source Roxee
| Refreshed May 5, 2026, 10:07 AM UTC
The storefront fact projection used for browse cards and quick facts.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Evidence
Reviewed / Updated / Sources
Reviewed by: Not available
Last reviewed: April 15, 2026
Updated: April 15, 2026, 10:04 AM UTC
- FDA Dear Veterinarian safety warning for Senvelgo. · safety_warning
- openFDA case USA-USFDACVM-2025-US-065173 · adverse_reaction
- Official label · document
- Safety communication · document
- Safety communication · document
Velagliflozin Proline Monohydrate
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Boehringer Ingelheim Animal Health USA Inc.
Medication Snapshot
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Velagliflozin Proline Monohydrate
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. Species commonly shown: Cats.
Indications / Uses
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus.
Administration / How To Give
Give Senvelgo by mouth once daily at approximately the same time each day, with or without food, as directed by a veterinarian.
Warnings / Contraindications
Do not use Senvelgo in cats with diabetes mellitus who have previously been treated with insulin, are receiving insulin, or have insulin-dependent diabetes mellitus; do not start it in cats that are anorexic, dehydrated, or lethargic.
- Cats treated with Senvelgo may be at increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, which can result in death and requires prompt veterinary treatment.
Side Effects
Top reported reactions (openFDA): Overdose, Diarrhoea, Vomiting, Hypersalivation, Wound, Dermal cyst(s).
FAQ
Source Transparency
- Verified source: https://www.roxee.ai/meds/
- Verified source: https://animaldrugsatfda.fda.gov
- Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
- Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/monthlyUpdates/downloadMonthlyUpdate/1621
- Verified source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boehringer-ingelheim-animal-health-usa-inc-695225-01032025
- Verified source: https://api.fda.gov/animalandveterinary/event.json
- Last refreshed: May 5, 2026, 10:07 a.m.
- Last verified: Apr 15, 2026, 10:04 a.m.
- Validation status: Complete
Add to My Pet's Meds
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continuePet Owner Quick Guide
Start here first for the safest next-step summary before the deeper medication detail.
Used for:
Your vet decides this. Here's what owners typically ask/watch for.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
- Ketosis (1 reports)
- Increased urine concentration (1 reports)
- Hypotension (1 reports)
When to call the vet:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Trouble breathing.
- Facial swelling or hives.
- Blood in vomit or stool.
What to tell or ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs
Side effects to monitor:
- Ketosis
- Increased urine concentration
- Hypotension
Most reported reactions:
- Ketosis (1 reports)
- Increased urine concentration (1 reports)
- Hypotension (1 reports)
Emergency warning signs:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Trouble breathing.
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Grouped by Body System
Most Reported Reactions
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 |
Species coverage: Cat (29) Dog (3)
View detailed reaction table
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Effectiveness | Cat | Non-serious | - | 1 | |
| Effectiveness | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-065173
Documents
Owner handouts and official technical documents open on-page first, with the original source still one click away.
Owner handouts
0Official label / PI
4SPL
1FOI
1Animal Drugs @ FDA search portal
Official label / PI · Official label
This source does not expose a safe inline preview. Use the original source link for the full document.
Official FDA veterinary drug portal.
FDA Owner Guidance for Diabetes Drugs in Cats
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
FDA owner-facing guidance for Bexacat and Senvelgo in diabetic cats.
FDA Dear Veterinarian Letter for Senvelgo
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
FDA safety communication for veterinarians using Senvelgo.
FDA CVM Warning Letter (Senvelgo context)
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
Official FDA communication referencing Senvelgo and sponsor.
Senvelgo SPL
SPL · Structured Product Label
Senvelgo FOI Summary (FDA)
FOI · FOI summary
- https://animaldrugsatfda.fda.gov/adafda/views/#/search · document · Official label
- https://www.fda.gov/animal-veterinary/animal-health-literacy/two-new-drugs-treat-diabetes-cats-one-right-your-cat · document · Safety communication
- https://www.fda.gov/animal-veterinary/product-safety-information/dear-veterinarian-letter-regarding-important-safety-conditions-associated-use-senvelgo-velagliflozin · document · Safety communication
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boehringer-ingelheim-animal-health-usa-inc-695225-01032025 · document · Safety communication
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14320 · document · FOI summary
- https://www.accessdata.fda.gov/spl/data/2ff66b67-9b85-4827-a5cb-0f7307c72b77/2ff66b67-9b85-4827-a5cb-0f7307c72b77.xml · document · Structured Product Label
Veterinary reference (advanced)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
-
Storefront facts:
Source Roxee
| Refreshed May 5, 2026, 10:07 AM UTC
The storefront fact projection used for browse cards and quick facts.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0010-4614-01 | 0010 | - | |
| 0010-4614-02 | 0010 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
Animal Drugs @ FDA search portal
• Official label • Official
Official FDA veterinary drug portal.
-
FDA Owner Guidance for Diabetes Drugs in Cats
• Safety communication • Official
FDA owner-facing guidance for Bexacat and Senvelgo in diabetic cats.
-
FDA Dear Veterinarian Letter for Senvelgo
• Safety communication • Official
FDA safety communication for veterinarians using Senvelgo.
-
FDA CVM Warning Letter (Senvelgo context)
• Safety communication • Official
Official FDA communication referencing Senvelgo and sponsor.
-
Senvelgo FOI Summary (FDA)
• FOI summary • Official
Official FDA Freedom of Information summary for NADA 141-568.
-
Senvelgo SPL
• Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Data Sources & Change Log
Every non-trivial field is expected to include provenance and update timestamps.
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-05-01)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-30)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-14)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-12)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-11)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-10)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-10)
- monitoring updated 2026-05-05 10:07 by curated_loader • FDA monitoring and urgent-action guidance for Senvelgo.
- contraindications updated 2026-05-05 10:07 by curated_loader • FDA contraindication and warning summary for Senvelgo.
- prescription_required updated 2026-05-05 10:07 by curated_loader • FDA original approval lists Senvelgo marketing status as Rx.
- administration updated 2026-05-05 10:07 by curated_loader • FDA owner-facing guidance for giving Bexacat or Senvelgo.
- strengths updated 2026-05-05 10:07 by curated_loader • FDA original approval lists Senvelgo concentration as 15 mg/mL.
- dosage_forms updated 2026-05-05 10:07 by curated_loader • FDA original approval lists Senvelgo drug form as solution.
- species updated 2026-05-05 10:07 by curated_loader • FDA original approval lists Senvelgo species as cats.
- usage updated 2026-05-05 10:07 by curated_loader • FDA original approval indication for Senvelgo.
- drug_profile_type updated 2026-05-05 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
- manufacturer_name updated 2026-05-05 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
- brand_names updated 2026-05-05 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
- approval_reference updated 2026-05-05 10:07 by curated_loader • Official FDA application reference for Senvelgo.
- monitoring updated 2026-05-03 10:07 by curated_loader • FDA monitoring and urgent-action guidance for Senvelgo.
- contraindications updated 2026-05-03 10:07 by curated_loader • FDA contraindication and warning summary for Senvelgo.
- prescription_required updated 2026-05-03 10:07 by curated_loader • FDA original approval lists Senvelgo marketing status as Rx.
- administration updated 2026-05-03 10:07 by curated_loader • FDA owner-facing guidance for giving Bexacat or Senvelgo.
- strengths updated 2026-05-03 10:07 by curated_loader • FDA original approval lists Senvelgo concentration as 15 mg/mL.
- dosage_forms updated 2026-05-03 10:07 by curated_loader • FDA original approval lists Senvelgo drug form as solution.
- species updated 2026-05-03 10:07 by curated_loader • FDA original approval lists Senvelgo species as cats.
- usage updated 2026-05-03 10:07 by curated_loader • FDA original approval indication for Senvelgo.
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|
Data source: FDA Animal Drugs @ FDA (public search export).
Top Reported Reactions (openFDA)
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Behavior.
Showing top 5 for Effectiveness.
Show more (21)
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Cat, Maine Coon, Female, 11 week, 5.035 kilogram • Drug: MSK, Solution, Oral, Dose: 0.40 mL per animal • Reactions: Not eating, Tiredness (lethargy), Fever, Decreased percentage of reticulocytes, Leucocytosis NOS… • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-075502
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 11.00 Week
- Weight: 5.035 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 0.40 mL per animal
Cat, Maine Coon, Male, 8 year, 9.117 kilogram • Drug: MSK, Solution, Oral, Dose: 0.99 Milligram per kilogram, Frequency: 1 per day • Reactions: Diarrhea, Bloody diarrhoea, Polyuria, Polydipsia • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-075501
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 8.00 Year
- Weight: 9.117 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 0.99 Milligram per kilogram
- Frequency: 1 per day
Cat, Siamese, Male, 7 year, 6.759 kilogram • Drug: MSK, Solution, Oral, Frequency: 1 per day • Reactions: Soft stool, Hypoglycaemia • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-075104
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 7.00 Year
- Weight: 6.759 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Frequency: 1 per day
Cat, Domestic Longhair, Male, 12 year, 3.629 kilogram • Drug: MSK, Solution, Oral • Reactions: Ketosis • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-075099
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 12.00 Year
- Weight: 3.629 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
Cat, Domestic Shorthair, Male, 11 year, 5.398 kilogram • Drug: MSK, Solution, Oral • Reactions: Polyphagia, Ketosis • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-075092
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 11.00 Year
- Weight: 5.398 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
Cat, Domestic Shorthair, Male, 8 year, 6.35 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Diarrhea • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-074759
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 8.00 Year
- Weight: 6.350 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 1 Milligram per kilogram
- Frequency: 1 per day
Cat, Domestic Shorthair, Male, 6 year, 4.6 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 24 per hour • Reactions: Diarrhea • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-074006
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 6.00 Year
- Weight: 4.600 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 1 Milligram per kilogram
- Frequency: 24 per hour
Cat, Domestic Shorthair, Male, 12 year, 4.767 kilogram • Drug: MSK, Solution, Oral, Dose: 0.99 Milligram per kilogram • Reactions: Ketosis, Diabetic ketoacidosis • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-073997
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 12.00 Year
- Weight: 4.767 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 0.99 Milligram per kilogram
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.